H ealth plans constitute themselves largely through the health care services and products they cover for their members. These services and products are thus a subset of all potential services and products available from the market. In deciding to cover a subset of these services and products, health plans must set limits to coverage (e.g., only products and services typically used for restoring or maintaining health within resource constraints). These decisions reflect the general aims of the plan for a particular member group, whether these aims prioritize recruiting and retaining employees, expanding the base of covered lives for a health insurance carrier, advancing the health of fellow members in a union or retirement system, or complying with societal obligations to care for specific populations such as the elderly and the indigent. Although the decisions made for these groups can be different based on different general aims, they are nonetheless derived mainly from population parameters presented as frequencies, averages, correlations, maximums, minimums, and the like.
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Coverage policies drawn from these parameters typically assume homogeneity within the plan member group. In reality, however, these groups are heterogeneous to a degree, thus, preventing coverage policies from fully representing a plan's general aims. As a result, some individual plan members may not receive coverage for certain products and services based on population parameters, despite the intended coverage outlined in the plan's general aims. A health plan striving to achieve its aims, in turn, will have to consciously manage for heterogeneity within populations it serves. This commentary will offer some perspectives on how plans may choose to manage this heterogeneity when making decisions about prescription drug coverage policy.
■■ Determining Prescription Drug Coverage Policies-Setting Limits
Health plans typically aim to provide the services and products their members require to restore or maintain health. However, plans must limit the services and products they cover because (a) these are available for other uses than for restoring and C O M M E N TA R Y maintaining health, and (b) members may demand more than a plan can or should provide. As a consequence, plans must make decisions about the services and products to provide generally and, more specifically, to determine who is eligible to receive them and under what circumstances.
Health plans make coverage policy decisions for their member groups (i.e., member populations). When making decisions for a group of individuals, population parameters are a natural factor to consider. However, making decisions based solely on population parameters without considering heterogeneity within these populations may result in individual plan members not having access to services and products they otherwise would have had, if the decisions more closely reflected the general aims of the plan. Coverage policy decision making requires more precision to achieve a plan's general aims than the inferences drawn from population parameters. Policy decisions for individual drugs and different drug categories are examples of how to apply more precision in decision making to address heterogeneity within covered populations. 1 Coverage decisions at the level of drug categories are an indicator of the general scope of a health plan coverage policy for prescription drugs. For example, plans aiming to address persons with diabetes will cover antidiabetic drug classes, while plans choosing not to address obesity will exclude coverage of weight-loss drug classes. Decisions at this level correspond to homogeneous patient populations where persons with diabetes represent one population while overweight individuals represent another; put another way, these conditions are viewed as mutually exclusive. Yet, many individuals who are overweight also have diabetes, so these conditions may not be mutually exclusive. The plan aiming to cover treatments for diabetes but not for weight loss will fail to cover related services and products by considering the weight-loss population as homogeneous. To fully manage to its general aims, then, the plan would need to accommodate these individuals in need of weight reduction treatments to aid in their diabetes control. As a general principle, it is important to consider the effects on individual need when determining coverage policies for populations. 2 Plans make decisions about the coverage of individual drugs within covered drug categories. These decisions are based on implicit or explicit comparisons among medications. Certain drugs within a category may be favored over others because they provide better clinical outcomes or offer significant cost advantages. In essence, plans rely on comparative effectiveness research (CER) whenever possible to discern those drugs with clinical advantages over others and, in instances where they are considered clinically interchangeable enough, to create or capture any available cost advantages.
SUMMARY
Necessity and fairness require that health plans limit the products and services they cover. The basis for these decisions refers to population averages and related population parameters. However, individuals vary and may not be accurately represented by the parameters used to establish coverage policies. Health plans, therefore, are obligated to anticipate and manage heterogeneity among their member groups. This commentary offers considerations for managing heterogeneity in prescription drug benefits.
Those charged with developing prescription drug coverage policies for particular groups will most likely base many of their decisions on population parameters. Indeed, using population parameters will result in coverage policies that address most of the needs of most people most of the time. However, the health care situations of some individuals do not aggregate neatly or reliably in ways that are captured by population parameters. In addition, the language available to describe coverage policy decisions may be insufficient to compensate for those situations that fail to conform to the population parameters. For these reasons as well as others, using population parameters solely for coverage policy will result in some people not having access to services and products they are legitimately entitled to, according to the general aims of the plan. In summary, although health plan policies are developed for populations, they are administered for individuals; therefore, health plans providing prescription drug coverage policies have an obligation to anticipate and manage heterogeneity. With appropriate consideration, principles and policies to accommodate heterogeneity can improve the health outcomes for the entire population by protecting individuals from unintended hindrances to health care coverage.
CER may generate concerns when it is used to make coverage policy decisions because of its reliance on population effects. Specifically, population effects may obscure the benefits or risks for an individual patient when the treatment that generally works for the population is less effective or more expensive than other treatments, or when patients are more likely to experience adverse effects. 3 This variability is a valid concern; however, the value of CER to health plans endeavoring to make the best clinical and economic decisions is real and important. Thus, in using CER to design coverage policy for individual drugs, health plans must diligently manage the effects of the inherent heterogeneity involved. This necessity means that plans need to seek and accommodate sources of heterogeneity within populations affected by coverage decisions (i.e., identify the treatment populations that generate wide ranges around average effects and what drives those ranges). Plans also need to put appeals processes in place to address heterogeneity that is unforeseeable but is likely to manifest once a coverage policy is in place.
■■ Managing Heterogeneity Through Fair Processes
In the United States, several different types of organizations serve as health plans that decide what health care services and products to cover for certain groups. These organizations include government agencies, employers, insurance carriers, managed care organizations, union groups, and retirement systems, to name a few. Various motivations and requirements provide the basis for these decisions. Furthermore, none of these organizations can refer to a set of distributive justice principles to guide their decisions-principles that produce clear and unambiguous priorities for those who are the sickest or those who will achieve the best outcomes as they manifest, for example, in clinical results or in social utility. As a result, considerable variation exists among prescription drug coverage policies that present individuals with a bewildering array of choices and seemingly irrational limits. Understandably, plan members may question the legitimacy and fairness involved in their plan's development. 4 In the absence of distributive justice principles and given the variation among coverage policies, leading experts in allocating coverage policy decisions for health services have suggested the need for a set of procedures that are considered fair by those who are affected by them. These procedures include the following: making individual coverage policy decisions public to those affected by them; requiring that decisions to limit coverage in specific ways are relevant to the purpose of the plan; revising coverage decisions as new information becomes available; enabling mechanisms for appeals; and applying policies impartially while addressing conflicts of interest. Accommodating heterogeneity is clearly anticipated in these processes where coverage policies should be revised when heterogeneity results in exclusions inconsistent with plan general aims.
